-
OncoC4’s Cesalatamig Receives FDA Fast Track Designation for Cancer Treatment
A Major Milestone in Oncology Research OncoC4, Inc. has recently announced a significant advancement in its clinical development pipeline. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s investigational drug, cesalatamig. This designation is a vital step forward for patients battling cancer, as it is designed to facilitate the…